Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 9/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.39 |
| ▸ | MTOR | P42345 | 9/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.39 |
| ▸ | ABL1 | P00519 | 7/20 | 0.39 |
| ▸ | EGFR | P00533 | 7/20 | 0.39 |
| ▸ | HCK | P08631 | 7/20 | 0.39 |
| ▸ | SRC | P12931 | 7/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.39 |
| ▸ | PRKDC | P78527 | 7/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 6/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 3/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23917271 | 0.85 | BTK (0.40) | KDRPIK3CAMTORPIK3CDABL1 | |
| SCHEMBL13829837 | 0.84 | FLT3 (0.44) | KDRABL1SRCRETLCK | |
| SCHEMBL9010 | 0.81 | PIK3CG (0.54) | KDRPIK3CAMTORPIK3CDABL1 | |
| SCHEMBL19414399 | 0.79 | FLT3 (0.44) | KDRPIK3CAMTORPIK3CDABL1 | |
| SCHEMBL11928101 | 0.79 | PIK3CD (0.56) | KDRPIK3CAMTORPIK3CDABL1 | |
| SCHEMBL11306 | 0.78 | SRC (0.47) | KDRPIK3CAMTORPIK3CDABL1 | |
| SCHEMBL23917241 | 0.78 | PIK3CD (0.57) | KDRPIK3CAMTORPIK3CDABL1 | |
| SCHEMBL13717800 | 0.78 | CSNK1E (0.45) | KDRPIK3CAMTORPIK3CDABL1 | |
| SCHEMBL13828355 | 0.77 | PIK3CD (0.60) | KDRPIK3CAMTORPIK3CDABL1 | |
| SCHEMBL20093476 | 0.77 | VRK1 (0.41) | KDRPIK3CAMTORPIK3CDABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2021-06-01 | — | — | US | disclosed |
| US-20190282581-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10220035-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | FAAH 4426/4885KDR 1139/4885PIK3CA 88/4885 |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | MAP4K2, MAP3K20, MAP3K1 | FAAH 3183/4885KDR 1206/4885PIK3CA 221/4885 |
| US-10220035-B2 | Compounds as modulators of protein kinases | PRKCA, PRKCH, PRKCE | FAAH 4398/4885KDR 1236/4885PIK3CA 64/4885 |
| US-20190282581-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | FAAH 4426/4885KDR 1139/4885PIK3CA 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.